|Bid||155.34 x 100|
|Ask||157.65 x 100|
|Day's Range||155.26 - 157.94|
|52 Week Range||80.06 - 167.86|
|PE Ratio (TTM)||202.31|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Jeffrey M Leiden sold 99,563 shares of VRTX on 01/16/2018 at an average price of $156.99 a share.
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? On October 25, 2017, Vertex Pharmaceuticals (VRTX) announced positive top-line results from its open-label Phase 3 trial that evaluated Orkambi in 60 children suffering with cystic fibrosis (or CF) who have two copies of the F508del mutation. The trial reached its primary endpoint of safety, and Orkambi demonstrated improvement in secondary endpoints such as nutritional status and sweat chloride.
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.
Should Investors Be Interested in Vertex Pharmaceuticals in 2018? In 3Q17, Vertex Pharmaceuticals (VRTX) reported non-GAAP (generally accepted accounting principals) net profits of ~$136 million, which is a YoY (year-over-year) growth of ~216.3%, driven mainly by the rapid rise in total cystic fibrosis (or CF) drug sales. The company reported non-GAAP combined SG&A (selling, general, and administrative) and R&D (research and development) expenses of ~$334 million, which is a YoY rise of 13.2%.
Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.
Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) released its most recent earnings update in September 2017, which signalled that losses became smaller relative to the prrior year’s level as a result of recentRead More...
Vertex Pharmaceuticals (NASDAQ: VRTX ) releases its next round of earnings Monday, Jan. 8. Here's Benzinga's essential guide to Vertex's Q4 earnings report. Earnings and Revenue Based on Vertex management ...
If you were lucky enough to own these healthcare stocks, then your returns more than tripled the S&P 500 last year.